Latest figures show that new Medicare coverage has significantly broadened access to GLP 1 medicines for seniors. Since its introduction in July, approximately 700,000 new senior patients have begun taking these important drugs. This expansion demonstrates the program's immediate effect on patient treatment options.
The Eli Lilly CEO confirmed these metrics, highlighting the company's strong performance within this new market segment. Of the hundreds of thousands of seniors who have started GLP 1 treatments under the new Medicare plan, a substantial 70 percent have selected drugs manufactured by Eli Lilly. This indicates a significant market share for the pharmaceutical company following the policy change.